Skip to content
Menu

CERo Therapeutics Holdings, Inc. CERO

Full chart Compare
Set alert

Price alert · CERO

All alert types
0.00 USD 0.00 (+5.41%)

As ofNov 20, 2026, 2:20 PM EST

0.0039 Day range 0.0043
0.003 52-week range 0.135
YTD
-94.18%
1 year
-93.50%

 

No chart data for this range yet.
Market cap
324.91K
EPS (ttm)
49.74
Shares out
150.31M
P/E ratio
0.00
YTD return
-94.18%
1-year return
-93.50%
50-day average
0.12674
Volume
33.33K
Avg volume
577.75K
Open
0.0043
Previous close
0.0037
Day's range
0.0039 – 0.0043
52-week range
0.003 – 0.135
Beta
-0.46

Key statistics

200-day average
0.62712
Enterprise value
20.56M
Free cash flow
14.46M
Total cash
3.65M
Total debt
2.15M
Short % of float
2.08%

Fundamental scorecard

2 of 25 checks passed on CERO’s reported financials

ValueGrowthProfitabilityHealthDividend

2of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2025.

Financials — quick view

All financials
CERO Revenue — quarterly 0
CERO Net income — quarterly -5.42M
CERO EPS — quarterly -61.71

About CERo Therapeutics Holdings, Inc.

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
cero.bio

News

Your note

Sign in to keep a note on CERO — it syncs with the Stock Master app.

Insider holders

CERO insider holders
InsiderRelationLatest transactionDateShares held
ATWOOD BRIAN GDirectorConversion of Exercise of derivative securitySep 24, 20240
EHRLICH CHRISTOPHER BChief Executive OfficerConversion of Exercise of derivative securitySep 24, 20245,795,410
LAPORTE KATHLEEN DDirectorConversion of Exercise of derivative securitySep 24, 20240
SLOAN STUART MBeneficial Owner of more than 10% of a Class of SecuritySaleSep 24, 20240
YK BIOVENTURES OPPORTUNITIES GP I, L.L.C.Beneficial Owner of more than 10% of a Class of SecuritySaleDec 12, 20240

Institution ownership

CERO institution ownership
Holder% heldSharesValueReported
Arch Venture Management, Llc0.96%1,444,29672.94KSep 29, 2024
Avantax Planning Partners, Inc.0.91%1,361,13068.74KSep 29, 2024
Geode Capital Management, LLC0.10%157,4457.95KSep 29, 2024
Selkirk Management Llc0.08%121,0406.11KSep 29, 2024
HRT Financial LP0.05%79,5624.02KSep 29, 2024
Fifth Lane Capital, LP0.05%76,5933.87KSep 29, 2024

Fund ownership

CERO fund ownership
Holder% heldSharesValueReported
Fidelity Extended Market Index Fund0.10%144,1457.28KOct 30, 2024